AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer
In-Situ Cancer Vaccine: Phase IIA, Open-Label Study to Assess the Safety of AlloStim® Immunotherapy Alone and in Combination With Cryoablation as Third Line Therapy for Metastatic Colorectal Cancer
Sponsor: Mirror Biologics, Inc.
This PHASE2 trial investigates Colorectal Cancer Metastatic and is currently completed. Mirror Biologics, Inc. leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Jun 2025 — Present [monthly]
Completed PHASE2
-
May 2025 — Jun 2025 [monthly]
Completed PHASE2
-
Sep 2024 — May 2025 [monthly]
Completed PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Nov 2018 — Feb 2020 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mirror Biologics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .